Lincoln Pharmaceuticals per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹48.38₹43.88₹41.11₹46.58₹36.40
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹48.38₹43.88₹41.11₹46.58₹36.40
₹378.25₹378.25₹335.34₹295.98₹250.86
₹360.58₹335.02₹311.15₹289.84₹254.78
—₹53.10₹46.44₹31.56₹19.60
₹40.10₹40.10₹36.94₹11.85₹12.47
—₹1.80₹1.80₹1.50₹1.50
2.02.02.02.02.0
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LINCOLN₹558.10

Lincoln Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersSIGACHITHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYAHCLMcap ₹1,118 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS36.4046.5841.1143.8848.38
Diluted EPS36.4046.5841.1143.8848.38
Book Value per Share250.86295.98335.34378.25378.25
Revenue per Share254.78289.84311.15335.02360.58
Cash Flow per Share19.6031.5646.4453.10—
Free Cash Flow per Share12.4711.8536.9440.1040.10
Dividends per Share1.501.501.801.80—
Shares Outstanding (cr)2.02.02.02.02.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.